Literature DB >> 23152586

Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease.

Joshua M Milber1, Joseph V Noorigian, James F Morley, Helen Petrovitch, Lon White, G Webster Ross, John E Duda.   

Abstract

OBJECTIVE: To determine whether evidence of neuronal dysfunction or demise preceded deposition of Lewy pathology in vulnerable neurons in Parkinson disease (PD).
METHODS: We examined the extent of nigral dysfunction and degeneration among 63 normal, incidental Lewy body disease (ILBD), and PD cases based on tyrosine hydroxylase (TH) immunoreactivity and neuron densities, respectively. The relationship between these markers and Lewy pathology (LP) burden in the substantia nigra (SN) and Braak PD stage was assessed.
RESULTS: Compared with normal subjects, ILBD cases displayed a significantly higher percentage of TH-negative cells and lower neuronal densities in the SN as early as Braak PD stages 1 and 2, before LP deposition in the nigrostriatal system. ILBD nigral neuron densities were intermediate between normal subjects and PD cases, and TH-negative percentages were higher in ILBD than either normal or PD cases. Furthermore, neuron density and neuronal dysfunction levels remained relatively constant across Braak PD stages in ILBD.
CONCLUSIONS: These results suggest that significant neurodegeneration and cellular dysfunction precede LP in the SN, challenging the pathogenic role of LP in PD and the assumption that ILBD always represents preclinical PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152586      PMCID: PMC3578379          DOI: 10.1212/WNL.0b013e318278fe32

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Research diagnostic criteria for Parkinson's disease.

Authors:  C D Ward; W R Gibb
Journal:  Adv Neurol       Date:  1990

2.  Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men.

Authors:  D M Morens; J W Davis; A Grandinetti; G W Ross; J S Popper; L R White
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

3.  Association of coffee and caffeine intake with the risk of Parkinson disease.

Authors:  G W Ross; R D Abbott; H Petrovitch; D M Morens; A Grandinetti; K H Tung; C M Tanner; K H Masaki; P L Blanchette; J D Curb; J S Popper; L R White
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

Review 4.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 5.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.

Authors:  Dennis W Dickson; Heiko Braak; John E Duda; Charles Duyckaerts; Thomas Gasser; Glenda M Halliday; John Hardy; James B Leverenz; Kelly Del Tredici; Zbigniew K Wszolek; Irene Litvan
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

6.  Incidental Lewy body disease and preclinical Parkinson disease.

Authors:  Anthony DelleDonne; Kevin J Klos; Hiroshige Fujishiro; Zeshan Ahmed; Joseph E Parisi; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Zbigniew K Wszolek; Ryan J Uitti; J Eric Ahlskog; Dennis W Dickson
Journal:  Arch Neurol       Date:  2008-08

7.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

8.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

9.  Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease.

Authors:  G M Halliday; D A McRitchie; H Cartwright; R Pamphlett; M A Hely; J G Morris
Journal:  J Clin Neurosci       Date:  1996-01       Impact factor: 1.961

10.  Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.

Authors:  Dennis W Dickson; Hiroshige Fujishiro; Anthony DelleDonne; Joshua Menke; Zeshan Ahmed; Kevin J Klos; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Joseph E Parisi; J Eric Ahlskog
Journal:  Acta Neuropathol       Date:  2008-02-09       Impact factor: 17.088

View more
  48 in total

1.  Alpha-synuclein: prion or prion-like?

Authors:  Rehana K Leak; Matthew P Frosch; Thomas G Beach; Glenda M Halliday
Journal:  Acta Neuropathol       Date:  2019-08-12       Impact factor: 17.088

Review 2.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

Review 3.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

4.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

5.  Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

Authors:  David G Coughlin; Helen Petrovitch; Lon R White; Joseph Noorigian; Kamal H Masaki; G Webster Ross; John E Duda
Journal:  Parkinsonism Relat Disord       Date:  2019-03-28       Impact factor: 4.891

6.  Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.

Authors:  Nancy J Butcher; Tim-Rasmus Kiehl; Lili-Naz Hazrati; Eva W C Chow; Ekaterina Rogaeva; Anthony E Lang; Anne S Bassett
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

Review 7.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 8.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

9.  Excessive daytime sleepiness and topographic expansion of Lewy pathology.

Authors:  Robert D Abbott; G Webster Ross; John E Duda; Chol Shin; Jane H Uyehara-Lock; Kamal H Masaki; Lenore J Launer; Lon R White; Caroline M Tanner; Helen Petrovitch
Journal:  Neurology       Date:  2019-08-30       Impact factor: 9.910

10.  E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.

Authors:  Ignacio Íñigo-Marco; Miguel Valencia; Laura Larrea; Ricardo Bugallo; Mikel Martínez-Goikoetxea; Iker Zuriguel; Montserrat Arrasate
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.